Mankind Pharma Receives ESG Rating of '71' from NSE Sustainability
Mankind Pharma received an ESG rating of 71 from NSE Sustainability for FY25, based on publicly available information. The company did not solicit this rating.
The ESG rating provides information about the company's sustainability practices but does not have an immediate or significant impact on the company's financials or operations.
The announcement is a disclosure of an ESG rating received by the company, which is neither inherently positive nor negative.
* Mankind Pharma has been assigned an Environmental, Social, and Governance (ESG) Rating of '71' by NSE Sustainability Ratings and Analytics Limited. * The rating was independently assigned by NSE Sustainability for FY25, based on publicly available information. * Mankind Pharma did not engage NSE Sustainability for this rating.
What to do with a filing like this
Mankind Pharma Limited filed this with the NSE as a statutory disclosure, categorised under esg reports. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mankind Pharma Limited. Read the original for the full detail.